Welcome to our dedicated page for Nugene Intl SEC filings (Ticker: NUGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nugene Intl Inc’s filings aren’t just paperwork—they’re a window into how a science-driven skincare brand funds R&D, prices anti-hair-loss serums, and handles executive stock sales. If you have ever Googled “Nugene Intl Inc insider trading Form 4 transactions” or wondered how to decode a “Nugene Intl Inc annual report 10-K simplified,” this page gives you the answers without the 300-page slog.
Stock Titan layers AI-powered summaries over every document, so “understanding Nugene Intl Inc SEC documents with AI” becomes routine. Need the latest “Nugene Intl Inc quarterly earnings report 10-Q filing” before the market opens? Our real-time feed posts it within seconds, then highlights revenue from customized creams, burn-treatment trial costs, and inventory turns. You can also set instant alerts for “Nugene Intl Inc Form 4 insider transactions real-time” to see when executives buy shares ahead of a new serum launch, or scan a “Nugene Intl Inc proxy statement executive compensation” to compare pay with R&D spending.
Here’s how professionals use the data:
- Track “Nugene Intl Inc earnings report filing analysis” to compare quarter-over-quarter product margin trends.
- Dive into a “Nugene Intl Inc 8-K material events explained” note to gauge impact of clinical trial updates.
- Follow “Nugene Intl Inc executive stock transactions Form 4” for sentiment signals around new product launches.
Every 10-K, 10-Q, 8-K, or Form 4 is parsed by our expert system, turning dense disclosures into clear insights. Complex filings made clear—so you can focus on decisions, not documentation.
Livento Group, Inc. (NUGN) reported it issued 1,000,000,000 common shares to its Chief Investment Officer, Michael Gregory Max Henriksen, on August 26, 2025. The shares were priced at $0.001 per share for a total purchase price of $1,000,000, pursuant to a Subscription Agreement dated August 19, 2025, which is included as Exhibit 1.0.
The filing is presented under Item 5.02 and notes the company’s common stock trades on OTC Pink under the symbol NUGN.
Livento Group (NUGN) insider Michael Gregory Max Henriksen reported a purchase of 2,000,000,000 common shares at $0.002 per share on 10/22/2025 (transaction code P).
Following the transaction, he directly beneficially owned 3,083,040,806 shares. The filing lists his role as Chief Investment Officer and was filed by one reporting person.
Livento Group (NUGN) reported an initial statement of beneficial ownership on Form 3 for Michael Gregory Max Henriksen. He is listed as an officer (Chief Investment Officer) and a 10% Owner.
The filing reports beneficial ownership of 3,083,040,806 shares of Common Stock and 250,000,000 shares of Series C Convertible Preferred Stock, each shown as Direct (D) ownership. The event date is 10/22/2025.
Livento Group, Inc. (NUGN) filed its Q3 2025 10‑Q, reporting quarterly revenues of $329,423 and a net loss of $225,085. Cost of revenues, led by amortization and professional fees, totaled $771,921, resulting in a gross loss of $442,498. Other income contributed $355,627 in the quarter.
For the nine months ended September 30, 2025, the company posted revenues of $876,211, other income of $891,227, and a net loss of $755,294. Management attributes performance to its AI software platform Elisee and a shift toward movie projects under BOXO, with movie-related inflows reflected in other income.
On the balance sheet, total assets were $44.5 million, including $42.7 million net fixed assets driven by intangible assets. Total liabilities were $2.8 million, and accumulated deficit stood at $21.1 million. Common shares outstanding were 2,279,753,594 as of September 30, 2025. The company reported no active legal proceedings.
FAQ
What is the current stock price of Nugene Intl (NUGN)?
What is the market cap of Nugene Intl (NUGN)?
